Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study to see if emicizumab protects Kids' joints from hemophilia damage

NCT ID NCT07190118

Disease control Sponsor: Hasan Kalyoncu University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study will follow 20 children with hemophilia A who are starting emicizumab treatment. Researchers will measure pain, joint health, balance, and mobility over time to see if the drug helps protect the musculoskeletal system. The goal is to understand whether emicizumab can reduce long-term joint problems in these children.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
emicizumab
What this could lead to
If successful, this could show that emicizumab helps protect joints and muscles in children with hemophilia A, potentially improving their long-term physical health.
What could go wrong
This is a small, early-stage study with only 20 participants and no control group. Results may not apply to all children with hemophilia A, and the treatment's long-term effects on joints are still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Feb 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Male patients under 18 years of age diagnosed with hemophilia A will constitute the study population.

Ages

1 year to 18 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children who are under 18 years of age, * Have been diagnosed with Hemophilia A by a physician, * Have a factor level of 1% (IU) or less, * Have inhibitors positive or negative, * Have no obstacles to starting subcutaneous (emicizumab) treatment, * Willing to participate in the study Exclusion Criteria: \- Children with a history of cerebrovascular bleeding who present any neurological findings that would prevent participation in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hemophilia A are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hemophilia A Musculoskeletal Abnormalities

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hemophilia A Musculoskeletal abnormalities Musculoskeletal assessment

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hasan Kalyoncu University

    Gaziantep, Gaziantep, (505) 090-5846, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.